ALPS Medical Breakthroughs ETF(SBIO)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$50.95
11/20/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for SBIO

11/20/2026: SBIO (1-star) is currently NOT-A-BUY. Pass it for now.

The ALPS Medical Breakthroughs ETF (SBIO) provides targeted exposure to small- and mid-cap biotechnology companies with drugs in Phase II or Phase III clinical trials. Its main strengths lie in its specialized index methodology that filters out early research risk while avoiding mega-cap pharma dilution, all at a reasonable 0.50% expense ratio. It functions primarily as a tactical satellite allocation to capture clinical milestones and sector M&A upside. Key risks include high volatility, binary clinical trial outcomes, and sensitivity to financing conditions. It suits aggressive growth investors comfortable with sector-specific concentration and drawdown risks.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

ETF holdings, costs, diversification, valuation, risks, and market conditions provide supporting context about the fund.

Investor Fit

Investor styleFitWhy
Growth investorStrong fitSuits growth-oriented mandates targeting high-potential scientific breakthroughs and clinical expansions.
Momentum investorStrong fit while signal remains positiveAppeals to momentum strategies during periods when biotech sentiment and clinical trial catalysts trend upward.
Value investorWeak fitPre-revenue clinical-stage firms frequently lack traditional earnings or fundamental value metrics.
Dividend/Income investorWeak fitPortfolio holdings reinvest cash flows into research and development rather than distributing dividends.
Low-risk investorWeak fitHigh volatility and binary clinical trial risks conflict with capital-preservation goals.

Investor Profile

Ideal Investor Profile

Growth-oriented or tactical sector investors seeking high-beta exposure to mid-stage drug development catalysts with a high tolerance for volatility.

Suitability

Best utilized as a tactical satellite allocation for experienced investors rather than a core long-term portfolio holding.

Risk Profile

Risk factorLevelWhy it matters
VolatilityHighClinical-stage biotechnology stocks experience severe price swings based on trial updates.
Market riskHighBroader equity market corrections can heavily compress valuations across speculative biotech sectors.
ConcentrationMedium / highThe fund is concentrated entirely within the clinical-stage biotechnology industry segment.
Tracking/expenseLowPassive index replication introduces minimal tracking error relative to its targeted benchmark.
LiquidityMedium / highLower average daily volume compared to broad market funds can increase execution costs.
Business/sector qualityHighMany constituent companies generate little to no revenue while relying heavily on external financing.

Sector & Industry Intelligence

This fund is not assigned to one sector.

Risk Analysis

Volatility

SBIO exhibits high historical volatility due to its exclusive focus on clinical-stage biotechnology firms whose valuations swing sharply on trial outcomes.

Market Risk

Underlying assets face acute risks including regulatory rejection, clinical trial failure, lack of commercial revenue, and sensitivity to risk-off market sentiment.

What the ETF Owns

Exposure TypeExposureWeight (%)Retail Investor Read
IndustrySmall- and Mid-Cap Clinical-Stage Biotechnology EquitiesProvides targeted exposure to clinical-stage biotech firms advancing innovative drug pipelines through Phase II and Phase III trials.
Cash/collateralCash and Cash EquivalentsMaintains minor liquidity buffers for daily administrative operations and dividend or corporate action flows.

Price Behavior

Rolling Over
PRICE PATH

Rolling Over

The price momentum is slowing down and beginning to turn downward.

Moderately Choppy
PRICE STABILITY

Moderately Choppy

The stock has experienced noticeable price swings while retaining some directional structure.

Analysis of Past Performance

Type ETF
Historic Profit 105.44%
Avg. Invested days 88
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 4.0
ETF Returns Performance Upturn Returns Performance icon 5.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/20/2026
Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.